|Table of Contents|

Mutation of BRAF V600E,NRAS,TERT gene in papillary thyroid cancer and the correlation with clinicopathological characteristics

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
769-773
Research Field:
Publishing date:

Info

Title:
Mutation of BRAF V600E,NRAS,TERT gene in papillary thyroid cancer and the correlation with clinicopathological characteristics
Author(s):
FAN Jing1; LYU Yonggang2; ZHAO Ge1; LI Songpeng1; LI Mengxuan1; KONG Jing1; WANG Ting1
1.Department of Thyroid,Breast and Vascular Surgery,Xijing Hospital,Air Force Medical University,Shaanxi Xi'an 710032,China;2.Department of Thyroid and Breast Surgery,the Affiliated Hospital of Northwest University,Xi'an No.3 Hospital,Shaanxi Xi'an 710018,China.
Keywords:
thyroid carcinoma; BRAF V600E; NRAS; TERT; pathological characteristics; correlation
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2021.05.011
Abstract:
Objective:To explore the mutation characteristics of BRAF V600E,NRAS,TERT genes and their association with clinicopathological features in thyroid cancer.Methods:Patients with thyroid cancer,admitted in Xijing Hospital,were enrolled into this study,between January 2018 and December 2018.All participants accepted BRAF V600E,NRAS and TERT gene detection.The mutation features were analyzed,as well as their clinical association with clinical characteristics.Results:347 patients were enrolled into this study.The mutation rate of BRAF V600E,TERT,NRAS genes were 89.3%,2.0% and 1.2%.TERT and NRAS mutation coexisted with BRAF V600E gene mutation.Double mutation rate of BRAF V600E/NRAS or BRAF V600E/TERT was 3.2%.Among 72.7% with BRAF V600E/NRAS or BRAF V600E/TERT co-mutation,72.7% were found to be non-PTMC with multiple lesions.Lymph node metastasis rate was 81.8%.All patients with BRAF V600E/NRAS co-mutation were found with lymph mode metastasis.71.4% patients with BRAF V600E/TERT double mutation had metastatic lymph nodes.Single-factor analysis showed that age,number and location of lesion,lymph node metastasis were associated with double mutation(P all＜0.05).Conclusion:The mutation rate of BRAF V600E was 89.3% in PTC.TERT and NRAS were always coexisted with BRAF V600E.Double gene mutation maybe related with the aggressiveness of PTC.

References:

[1]CABANILLAS ME,MCFADDEN DG,DURANTE C.Thyroid cancer［J］.Lancet,2016,388(10061):2783-2795.
[2]田文,郗洪庆.甲状腺癌病人生存现状分析［J］.中国实用外科杂志,2016,36(05):489-493. TIAN W,XI HQ.Analysis of the survival status of patients with thyroidcarcinoma［J］.China Academic Journal,2016,36(05):489-493.
[3]董芬,张彪,单广良.中国甲状腺癌的流行现状和影响因素［J］.中国癌症杂志,2016,26(01):47-52. DONG F,ZHANG B,SHAN GL.Distribution and risk factors of thyroid cancer in China［J］.China Oncology,2016,26(01):47-52.
[4]罗定远,欧阳能太.甲状腺癌分子诊断的现状与展望［J］.临床外科杂志,2020,28(03):285-288. LUO DY,OUYANG NT.The status and trends of molecular diagnosis in thyroid cancer［J］.J Clin Surg,2020,28(03):285-288.
[5]赵慧敏,王翠峰.甲状腺癌的分子诊断现状研究［J］.检验医学与临床,2020,17(08):1135-1138. ZHAO HM,WANG CF.Research of molecular diagnosis of thyroid carcinoma［J］.Lab Med Clin,2020,17(08):1135-1138.
[6]张茂杰,叶晖.BRAF基因在甲状腺癌中表达的研究［J］.医学综述,2020,26(05):930-934. ZHANG MJ,YE H.Study on expression of BRAF gene in thyroid cancer［J］.Medical Recapitulate,2020,26(05):930-934.
[7]XING M.BRAF mutation in thyroid cancer［J］.Endocr Relat Cancer,2005,12(2):245-262.
[8]LEE SE,HWANG TS,CHOI YL,et al.Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAF(V600E) mutation［J］.Thyroid,2017,27(6):802-810.
[9]SANTHANA MP,KHTHIR R,SOLNES LB,et al.The relationship of BRAF(V600E) mutation status to FDG PET/CT avidity in thyroid cancer:A review and meta-analysis［J］.Endocr Pract,2018,24(1):21-26.
[10]CZARNIECKA A,OCZKO-WOJCIECHOWSKA M,BARCZYRSKI M.BRAF V600E mutation in prognostication of papillary thyroid cancer（PTC) recurrence［J］.Gland Surg,2016,5(5):495-505.
[11]NIKIFOROV YE.Role of molecular markers in thyroid nodule management:Then and now［J］.Endocrine Practice,2017,23(8):979-988.
[12]ALZAHRANI AS,ALSAADI R,MURUGAN AK,et al.TERT promoter mutations in thyroid cancer［J］.Horm Cancer,2016,7(3):165-177.
[13]REN H,SHEN Y,HU D,et al.Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness,but not with lymph node metastasis［J］.Cancer Manag Res,2018,10:1005-1013.
[14]LIU R,XING M.TERT promoter mutations in thyroid cancer［J］.Endocrine-Related Cancer,2016,23(3):R143-R155.
[15]VUONG HG,ALTIBI AMA.Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis［J］.Clinical Endocrinology,2017,87(5):411-417.
[16]XING MZ.Genetic-guided risk assessment and management of thyroid cancer［J］.Endocrinol Metab Clin North Am,2019,48(1):109-124.
[17]CORTES JMR,ZERON HM.Genetics of thyroid disorders［J］.Folia Med（Plovdiv),2019,61(2):172-179.
[18]MELO M,GASPAR DA ROCHA A,BATISTA R,et al.TERT,BRAF,and NRAS in primary thyroid cancer and metastatic disease［J］.J Clin Endocrinol Metab,2017,102(6):1898-1907.
[19]ARGYROPOULOU M,VESKOUKIS AS,KARANATSIOU PM,et al.Low prevalence of TERT promoter,BRAF and RAS mutations in papillary thyroid cancer in the Greek population［J］.Pathology & Oncology Research,2018,26:347-354.

Memo

Memo:
陕西省社会发展科技攻关项目（编号：2016SF-298）；西京医院助推项目（编号：XJZT15Z09）；希思科临床肿瘤学研究基金（编号：Y-BMS2019-069）
Last Update: 2021-01-29